<DOC>
	<DOCNO>NCT01604291</DOCNO>
	<brief_summary>This multi-center , observational study evaluate efficacy safety dual triple therapy base Pegasys ( peginterferon alfa-2a ) patient chronic hepatitis C. Patients receive treatment either Pegasys plus ribavirin Pegasys plus ribavirin plus telaprevir/boceprevir observed duration treatment 24 week follow-up .</brief_summary>
	<brief_title>An Observational Study Dual Triple Therapies Based Pegasys ( Peginterferon Alfa-2a ) Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic hepatitis C ( genotype , na√Øve treatment experience , HCV monoinfected HCVHIV coinfected ) Receiving either dual therapy ( Pegasys plus ribavirin ) triple therapy ( Pegasys plus ribavirin plus telaprevir/boceprevir ) No contraindication Pegasys ribavirin therapy treatment regimen contain protease inhibitor ( telaprevir boceprevir ) detail local Prescribing Information Quantitative serum HCV RNA PCR test initiation treatment Hepatitis A/B coinfection Evidence severe illness , active malignancy , condition would make patient , opinion investigator , unsuitable study Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>